Ironwood Pharmaceuticals (IRWD) EBT Margin (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of EBT Margin data on file, last reported at 61.19% in Q1 2026.

• For the quarter ending Q1 2026, EBT Margin rose 14935.0% year-over-year to 61.19%; the trailing twelve-month figure through Mar 2026 stood at 2.85% (down 3677.0% YoY), and the FY2025 full-year result was 30.77%, down 7832.0% from the prior year.
• EBT Margin advanced to 61.19% in Q1 2026, from 336.83% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 139.03% in Q4 2024 to a low of 1002.24% in Q2 2023.
• A 5-year average of 53.64% and a median of 44.37% in 2025 frame the typical range for EBT Margin.
• Across the five-year window, EBT Margin plunged 105755 bps in 2023 and jumped 102223 bps in 2024, its largest moves.
• Tracing IRWD's EBT Margin over 5 years: stood at 67.41% in 2022, then sank by 348 bps to 166.88% in 2023, then jumped by 183 bps to 139.03% in 2024, then tumbled by 342 bps to 336.83% in 2025, then soared by 118 bps to 61.19% in 2026.
• Business Quant data shows IRWD's EBT Margin at 61.19% in Q1 2026, 336.83% in Q4 2025, and 55.73% in Q3 2025.